• Droia Ventures raises a new fund of EUR 220 million to target genetic diseases and expands leadership team with George Golumbeski

    Tuesday May 11th 2021

  • Biocartis receives EUR 1.4m grant to support development of new Idylla™ technology to unlock potential in molecular surveillance

    Tuesday May 11th 2021

  • Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme

    Tuesday May 11th 2021

  • CD3 and VIB enter into an exclusive license and research collaboration with SpringWorks Therapeutics to develop TEAD inhibitors for addressing biomarker-defined cancers

    Friday May 7th 2021

  • Biocartis announces new collaboration with AstraZeneca to expand availability of Idylla™ EGFR biomarker testing among patients with lung cancer

    Wednesday May 5th 2021

  • miDiagnostics accelerates with launch of rapid COVID-19 PCR test product

    Monday May 3rd 2021

  • New cancer immunotherapy treatment enters clinical phase

    Thursday April 29th 2021

  • Precirix partners with Evergreen to expand North American clinical trial supply

    Wednesday April 28th 2021

  • Your news here?

  • Gilead Sciences submits new drug application in Japan for filgotinib for the treatment of ulcerative colitis with an inadequate response to conventional therapies

    Friday April 23rd 2021

  • Biocartis and SkylineDx sign collaboration to develop the Merlin Assay

    Thursday April 22nd 2021

  • Biotalys appoints Simon Moroney as Chairman of the Board

    Wednesday April 21st 2021


Strategic Partners